RNAZ — Transcode Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1829635 ·
Last close
$1.41
Market Cap
$1.49M
52W High
$12.60
52W Low
$1.28
ADV30
28,619
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -6,208,728 -6,750,128 151,010,103 8,383,393 12,651,920
Mar 2026 0 — -17,615,194 -17,785,071 157,164,882 12,835,454 12,643,694
Dec 2025 0 — -6,485,234 -13,443,110 162,398,689 17,813,521 10,518,687
Sep 2025 0 — -4,539,026 -4,856,051 5,226,682 2,835,916 3,800,703

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-22,605,311
Investing CF
$-4,436
Financing CF
$23,618,325
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-39.40
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-122,398,191
Inventory
—
Receivables
$638
ST Investments
—
EBIT TTM
$-42,370,181
Pretax Income TTM
$-42,376,683
Interest Exp TTM
$6,502
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -17,915,044 -34,661,076 162,398,689 10,518,687 151,880,002 -19,516,229
Dec 2024 0 -15,136,633 -16,754,971 7,294,499 9,313,233 -2,018,734 -13,335,947
Dec 2023 0 -18,495,481 -18,546,095 5,169,701 3,528,887 1,640,814 -18,074,535
Dec 2022 0 -17,553,392 -17,564,968 7,587,986 4,347,290 3,240,696 -15,762,512

TTM Snapshot

Revenues TTM
$222,960
NetIncome TTM
$-42,834,360
OpCashFlow TTM
—
Assets (Latest)
$151,010,103
Forward EPS
$-0.60

Peers — same industry

TickerNameMarket CapLastDaily %
HCWB HCW Biologics Inc. $1.43M $0.78 —
CPMD CANNAPHARMARX, INC. $1.42M $0.00 —
ARTL ARTELO BIOSCIENCES, INC. $1.57M $1.68 —
EMMA Emmaus Life Sciences, Inc. $1.61M $0.02 —
GNPX Genprex, Inc. $1.37M $1.67 —

News headlines (Yahoo Finance, 1h cache)

TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio
2026-10-28 20:30 · Yahoo
TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026
2026-10-26 11:31 · Yahoo
Natera Partners With TransCode to Advance Colorectal Cancer Trial
2026-10-21 13:16 · Yahoo
TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026
2026-10-19 12:04 · Yahoo
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
2026-10-13 11:30 · Yahoo
TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology
2026-09-22 12:04 · Yahoo
Join Today's Live Investor Webinar with TransCode Therapeutics
2026-09-16 13:00 · Yahoo
TransCode Therapeutics Announces Leadership Transition
2026-09-10 20:10 · Yahoo
Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer
2026-09-03 13:00 · Yahoo
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
2026-08-07 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.